NUCLEO
The first agentic platform for oncology
San Francisco, United States · Founded 2025
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- nucleoresearch.com
- Last Round
- Pre-SeedOct 2025
- Rounds
- 1
About
Nucleo builds AI agents that extract oncological metrics from CT scans—including sarcopenia detection, body composition, and lesion classification—enabling 2,500x faster segmentation than manual workflows. Working with Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell, Nucleo aims to compress the cancer diagnostic interval from 9–11 weeks to under 10 days.
Summary
NUCLEO is an Artificial Intelligence company based in San Francisco, United States, founded in 2025. Its most recent funding was a Pre-Seed round in Oct 2025. Investors include Y Combinator.
Funding History
Oct 2025
Investors
Similar Companies
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Databricks provides a unified data and AI platform that helps enterprises build and run applicati...
Genesys empowers more than 8,000 organizations worldwide with Genesys Cloud, an agentic AI experi...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Palantir Technologies builds data integration and analytics platforms (Gotham and Foundry) for go...
Qlik helps organizations turn trusted, contextual data into insights and actions through an integ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nucleo"><img src="https://indexed.vc/api/badge/company/nucleo" alt="NUCLEO on Indexed.vc" width="260" height="76" /></a>